The Pfizer Clinical Research Unit (PCRU) in Brussels is seeking participants for a clinical trial of a study drug for the treatment of atopic dermatitis and asthma. 

The purpose is to find out whether the study medicine is safe and well-tolerated when given as multiple doses to adults with mild-to-moderate asthma.

Who may participate

This study is seeking male and female participants of non-childbearing potential.
You may not take part in this study if:


• You are younger than 18 years or older than 65 years, you weigh less than or equal to 50 kg or you are outside of the limits for Body Mass Index (16 – 32 kg/m2)
• You are suffering from severe asthma or from any allergy to a medicine.
• You used tobacco / nicotine-containing products within the last 12 months, or you have a positive cotinine test.
• You have had an acute infection (including respiratory tract infections) within 28 days before your planned first dose.


There are other requirements for participation in this study. Please read attentively the Informed Consent Document (ICD), more explanation will be provided by the study staff during the screening process

See calendar

Condition

Healthy

Age

18-65

Sex

Male and female of non-childbearing potential

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

What to expect

If this study may be a fit for you, you’ll be invited to a screening visit at our facility in Brussels, Belgium.

 

Part F:
The study part will last for about 12 weeks and consists of
• A screening examination.
• You will stay in the PCRU for 2 treatment periods for a total stay of 17 days and 16 nights in the PCRU.
• The follow up phone call will take place approximately 28–35 days after the last dosing.

You will be screened within 28 days prior to the first dose of study intervention.
Throughout the study, staff will closely monitor your health status and collect data.
You will not personally derive any benefit from your participation in this study, but the results obtained could be very important for the development of medicines and treatments which will benefit other people.

How long is the study?

Part F: 12 weeks

Compensation

For the entire study (Part F): € 5.000